Literature DB >> 21617231

Response of medulloblastoma cells to vincristine and lomustine: role of TRKC, CTNNB1 and STK15.

Zakia Shinwari1, Hindi Al-Hindi, Essam Al-Shail, Yasser Khafaga, Amani Al-Kofide, Nasser El-Kum, Abdelilah Aboussekhra.   

Abstract

BACKGROUND: Vincristine and lomustine are two important chemotherapeutic drugs used for the treatment of different types of neoplasms, including medulloblastomas.
MATERIALS AND METHODS: We investigated the effects of vincristine and lomustine on 12 primary medulloblastoma cell cultures and the DAOY cell line using the annexinV-flow cytometry and immunoblotting techniques, following treatment of cells for different periods of time.
RESULTS: Both drugs triggered apoptosis and cell cycle delay at the G(2)/M phase and also up-regulated p16. Furthermore, the expression of 8 different cancer-related genes were assessed and their mRNA and protein levels were found to be highly heterogeneous and did not correlate in several medulloblastoma cultures. Importantly, there was significant correlation between the level of cadherin-associated protein beta 1 (CTNNB1) and Aurora kinase A (STK15) proteins and neurotrophic tyrosine kinase receptor type 3 (TRKC) mRNA and the proportion of apoptosis induced by vincristine, the combination of both drugs, and lomustine, respectively.
CONCLUSION: These genes could be of great importance as therapeutic biomarkers during the treatment of medulloblastoma patients with vincristine and lomustine.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21617231

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

1.  Tropomyosin receptor kinase C (TrkC) expression in medulloblastoma: relation to the molecular subgroups and impact on treatment response.

Authors:  Carsten Friedrich; Tarek Shalaby; Christoph Oehler; Martin Pruschy; Burkhardt Seifert; Daniel Picard; Marc Remke; Monika Warmuth-Metz; Rolf-Dieter Kortmann; Stefan Rutkowski; Michael A Grotzer; André O von Bueren
Journal:  Childs Nerv Syst       Date:  2017-07-10       Impact factor: 1.475

2.  Inhibition of histone deacetylases sensitizes glioblastoma cells to lomustine.

Authors:  Mikkel Staberg; Signe Regner Michaelsen; Rikke Darling Rasmussen; Mette Villingshøj; Hans Skovgaard Poulsen; Petra Hamerlik
Journal:  Cell Oncol (Dordr)       Date:  2016-10-20       Impact factor: 6.730

3.  Targeting PI3K, FGFR, CDK4/6 Signaling Pathways Together With Cytostatics and Radiotherapy in Two Medulloblastoma Cell Lines.

Authors:  Monika Lukoseviciute; Henrietta Maier; Eleni Poulou-Sidiropoulou; Erika Rosendahl; Stefan Holzhauser; Tina Dalianis; Ourania N Kostopoulou
Journal:  Front Oncol       Date:  2021-09-24       Impact factor: 6.244

Review 4.  Immunosuppression in Medulloblastoma: Insights into Cancer Immunity and Immunotherapy.

Authors:  Zahraa F Audi; Zahraa Saker; Mahdi Rizk; Hisham F Bahmad; Sanaa M Nabha; Hayat Harati; Youssef Fares
Journal:  Curr Treat Options Oncol       Date:  2021-07-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.